USCOM LIMITED — Annual Report 2017

Aug 21, 2017

ASX Media Release

Growth strategy continues to deliver; 5th consecutive year of record revenues

SYDNEY, Australia, Monday 21[st] August 2017: For Uscom shareholders 2017 was the 5th successive year of record revenues while investing in development and regulatory preparation of 7 new products for release in FY 2018. It was a year in which the Uscom Board and Management continued to execute our growth strategy and set a course for continued growth. We have built the foundations for a great medical device Company.

Total Annual Income

==> picture [304 x 244] intentionally omitted <==

----- Start of picture text -----

$4,000,000
$3,498,959
$3,500,000
$2,936,504
$3,000,000
$2,500,000
$2,039,426
$2,000,000
$1,377,716
$1,500,000
$1,010,942
$1,000,000 $864,099
$500,000
$0
2012 2013 2014 2015 2016 2017
----- End of picture text -----

2017 Headlines:

1. Record sales, total revenues and cash receipts (5 years of consecutive record revenue growth)

2. Total revenue up 19% to $3.49M (5 year CAGR – +32% pa)

3. Cash receipts up 20% to $3.52M (4 year CAGR – +36% pa)

4. Net cash used in operating activities down 26% to $0.95M

5. Intermittent cash flow positivity

6. VWAP share price up 25% to 25c (5 year CAGR – +18% pa)

7. Uscom Europe total revenue growth 21% (from $0.58M to $0.70M)

8. Implementation of dual path China distribution model in preparation for BP+ and SpiroSonic CFDA

9. Seven new BP+ and SpiroSonic devices prepared for market and revenue in FY 2018

10. Establishment of new Sales, Marketing and Distribution division

11. 1000th USCOM 1A customer sale

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

ASX Media Release

For FY 2017 we delivered continued growth for shareholders while maintaining prudent and efficient use of resources as we continued the development of our 7 new products, prepared and submitted multiple regulatory applications, continued investment in product R&D, and met significant one off operational costs. Uscom has invested in strategic acquisitions, established a global corporate model, consolidated the Uscom Europe volume manufacturing facility, and prepared 7 new products as a growth platform for Uscom in FY 2018 and beyond. These investments have been made with existing resources and therefore the balance sheet remains debt free, and the forthcoming revenues from these investments are planned to reliably underwrite growth and shareholder value over the coming decade.

Uscom has established a culture of pursuing growth, informing investors, and executing on that strategy to the benefit of shareholders, and this is planned to continue as we target ongoing growth in FY 2018 with the release and sale of our 7 new products.

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote telemonitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary SpiroReporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse spirometry outputs and generate summary reports.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

ASX Media Release

Uscom Limited and its controlled entity ABN 35 091 028 090

ASX Preliminary final report – 30 June 2017

Contents

Results for announcement to the market	2
Dividends per share	2
Net Tangible Assets per ordinary share	2
Status of audit	2
Commentary	2
Financial highlights	2
Annual Report	Attached

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

ASX Media Release

Reporting period: Previous corresponding reporting period:

Financial year ended 30 June 2017 Financial year ended 30 June 2016

Results for announcement to the market

Revenues from ordinary activities	up	19%	to	$3,498,959
Lossfrom ordinary activities after tax attributable to members	down	6%	to	$1,800,849
Net Lossfor the period attributable to members	down	6%	to	$1,800,849

Dividends per Share

It is not proposed to pay a dividend.

Net Tangible Asset per Ordinary Share

	30	June 2017	30 June 2016
NTA backing		c0.022	c0.031

Status of audit

The accounts have been audited. The annual report, including the unqualified audit report is attached.

Commentary

Refer to Chairman’s Letter in 2017 Annual Report.

Financial highlights

Revenues from ordinary activities	$3,498,959
Loss from ordinary activities	$1,800,849
Sales Revenue	$2,723,359
Net operating cash outflow	$952,042
Net decrease in cash held	$1,176,208
Cash held at end of the year	$1,663,565

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au